Islet Transplantation Clinical Trial
Official title:
Extended Follow-Up After Islet Transplantation in Type 1 Diabetes (CIT-08)
The purpose of this study is to provide patients who have received at least one islet transplant as a previous participant in a Clinical Islet Transplantation Consortium (CIT) clinical trial with maintenance immunosuppressive medications and to collect information about the safety of the medications and islet function.
After islet-cell transplantation in the CIT studies*, each subject receives maintenance
immunosuppressive medications.
The purpose of this protocol is to collect additional follow-up for safety and efficacy from
CIT subjects with graft function after their completion in their CIT parent study. It is
expected that most subjects will retain measurable islet function and, in the islet-alone
studies, continue to receive immunosuppressive medications at the time of completing their
CIT parent study.
*CIT parent studies: CIT02 (NCT00464555), CIT03 (NCT00434850), CIT04 (NCT00468403), CIT05
(NCT00468442), CIT06 (NCT00468117), and CIT07 (NCT00434811)
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Withdrawn |
NCT01123122 -
A Comparison of Strict Glucose Control With Usual Care at the Time of Islet Cell Transplantation
|
N/A | |
| Completed |
NCT00417131 -
Imaging of Islet Transplantation With PET and MRT
|
N/A | |
| Not yet recruiting |
NCT05973734 -
Islet Transplantation With Recipient T-Reg Cells or Deceased Donor Vertebral Bone Marrow Therapy
|
Phase 1 | |
| Completed |
NCT02627690 -
Nephrologic Prognosis 10 Years After Diabetes Cell Therapy
|
||
| Terminated |
NCT00853944 -
Effect of Sitagliptin on Graft Function Following Islet Transplantation
|
Phase 3 | |
| Completed |
NCT03427931 -
CGM Use in Islet Transplant Recipients
|
N/A | |
| Terminated |
NCT00409461 -
Comparison of Sirolimus Alone With Sirolimus Plus Tacrolimus in Type 1 Diabetic Recipients of Cultured Islet Cell Grafts
|
N/A |